Liquidia Corp (LQDA) stock intrinsic value fair value estimate & owner earnings analysis

Liquidia is a specialty pharmaceutical company focused on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead product, YUTREPIA, is an inhaled dry-powder form of treprostinil that received final FDA approval in May 2025 for both indications, following a long approval and patent-litigation history with United Therapeutics, the maker of the competing Tyvaso and Tyvaso DPI products. The launch has been real and substantial, not promotional. Reported product revenue rose from about $14 million in 2024 to $158 million in 2025, and then to roughly $305 million in just the first half of 2026 alone – more than the entirety of 2025. The company reported its first two GAAP-profitable quarters in the first half of 2026 (net income of about $53 million and $75 million), together with operating cash flow of about $133 million over that six-month span. This is a company that has moved from cash-burning development stage to demonstrated profitability within about a year of launch. The most important risk is litigation, not commercial execution. United Therapeutics has sued Liquidia twice over patents covering inhaled treprostinil. In the first case (the '327 patent), a trial concluded in June 2025, post-trial briefing is complete, and a court ruling is still pending as of the most recent annual report; United Therapeutics is asking the court to force YUTREPIA off the market entirely, or at minimum to strip the PH-ILD indication from its label. A second suit (the '782 patent) is also proceeding after the court declined to dismiss it in December 2025. On the other hand, courts have twice already denied United Therapeutics' requests to immediately halt YUTREPIA sales while the cases proceed (in 2024 and again in 2025), and a third patent United Therapeutics originally asserted was found invalid on appeal. The outcome of the pending ruling could meaningfully change what YUTREPIA is allowed to treat. We valued the company under three scenarios. The base case assumes the litigation resolves without disrupting the current business, and that YUTREPIA's growth continues for a few more years as more patients and physicians switch from competing therapies, before leveling off as the addressable patient population matures; we did not assume any new products or indications beyond what already exists. The bear case assumes the pending ruling goes against Liquidia and the PH-ILD indication (the newer, larger opportunity) is removed from the label, leaving a smaller but still solidly profitable business built around the original PAH indication. The bull case assumes the litigation resolves fully in Liquidia's favor, similar to how the earlier patent claim was invalidated, allowing uninterrupted growth. In each case, growth is limited to what the current, already-launched indications can support; we have not credited value for unapproved pipeline products. On financing: Liquidia funded its launch partly through a royalty-style financing agreement that has provided about $175 million to date, repaid on a fixed quarterly schedule through 2033. This financing is expensive – its effective cost has run between roughly 14% and 18% a year – well above the 6% rate we use to value the business itself, so we increased the debt figure we subtract from the business value to reflect its true economic cost, rather than using its lower book value. Against that, the company held about $284 million of cash as of mid-2026, comfortably more than the adjusted obligation, leaving the company in a net cash position overall. The scheduled payments (roughly $30-60 million a year) are well within what the business is now generating in operating cash flow. Based on this, our fair-value estimates per share are approximately $18.50 in the bear case, $41.00 in the base case, and $59.50 in the bull case. Given how recent the swing to profitability is (two quarters), the binary nature of the pending litigation, and the size of the swing between our bear and bull cases, the margin-of-safety price is set at a large discount to our base-case estimate, at about $19, close to our bear-case estimate, which reflects a disappointing outcome on the pending litigation. A note on the numbers: a portion of the company's cash-flow reconciliation in some older, pre-launch years (2021-2023) contained a small (roughly 5-6%) unexplained gap between reported operating cash flow and the underlying income-statement and balance-sheet items, most likely tied to how a refund-liability line item was presented across periods. This does not affect 2025 or 2026 figures, which reconcile exactly, and none of the affected years were used to set the valuation level.